Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).

Mar 20, 2023

Experts: Robert Seifert,Louise Emmett,Steven P Rowe,Ken Herrmann,Boris Hadaschik,Jeremie Calais,Frederik L Giesel,Robert Reiter,Tobias Maurer,Matthias Heck,Andrei Gafita,Michael J Morris,Stefano Fanti,Wolfgang A Weber,Thomas A Hope,Michael S Hofman,Wolfgang Peter Fendler,Matthias Eiber

Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) is emerging to become a reference imaging tool for the staging and restaging of patients with prostate cancer for both clinical routine and trials. The prostate cancer molecular imaging standardized evaluation (PROMISE) criteria have been proposed as a framework for whole-body staging (molecular imaging TNM staging, denoted miTNM staging) to describe the prostate cancer disease extent on PSMA-PET.
To create a comprehensive and integrated framework for PSMA-PET image interpretation and reporting.
We propose the PROMISE V2 framework, which integrates an updated miTNM system, improved assessment of local disease, and a slightly modified PSMA-expression score for clinical routine. We have added a response monitoring framework defining qualitative and quantitative parameters to be recorded for a longitudinal assessment in clinical trials.
We provide a comprehensive literature review on the current use of the PROMISE framework in clinical research and prospective trials. PROMISE variables demonstrate a clear association with survival. PSMA expression assessed by the PSMA-expression score was used in several trials, and a low PSMA-expression score is a negative prognosticator of overall survival after Lu-PSMA radioligand therapy. The proposed imaging parameters recorded for response assessment in clinical trials can be utilized to determine response according to PSMA-PET progression (PPP) or Response Evaluation Criteria in PSMA-PET/Computed Tomography (RECIP) frameworks, but also future response criteria.
PROMISE V2 offers standardized reporting of disease extent for clinical routine and research. Parameters recorded within clinical trials facilitate objective response assessment.
Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) has become a standard imaging examination for prostate cancer. We propose a comprehensive framework for the analysis and reporting of PSMA-PET findings that will improve the communication between imaging experts and uro-oncologists.

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Author

admin

View all posts

ABOUT THE EXPERTS

Robert Seifert,Louise Emmett,Steven P Rowe,Ken Herrmann,Boris Hadaschik,Jeremie Calais,Frederik L Giesel,Robert Reiter,Tobias Maurer,Matthias Heck,Andrei Gafita,Michael J Morris,Stefano Fanti,Wolfgang A Weber,Thomas A Hope,Michael S Hofman,Wolfgang Peter Fendler,Matthias Eiber

Robert Seifert

Department of Nuclear Medicine, University Hospital Essen, Essen, Germany. Electronic address: robert.seifert@uk-essen.de.

Louise Emmett

Department of Theranostics and Nuclear Medicine, St Vincent’s Hospital, Sydney, NSW, Australia.

Steven P Rowe

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins, University School of Medicine, Baltimore, MD, USA; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Ken Herrmann

Department of Nuclear Medicine, University Hospital Essen, Essen, Germany; Ahmanson Translational Theranostics, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, CA, USA.

Boris Hadaschik

Department of Urology, University Hospital Essen, Essen, Germany.

Jeremie Calais

Ahmanson Translational Theranostics, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, CA, USA.

Frederik L Giesel

Department of Nuclear Medicine, University Hospital Düsseldorf, Düsseldorf, Germany.

Robert Reiter

Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Tobias Maurer

Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Matthias Heck

Department of Urology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany; Bavarian Cancer Research Center (BZKF), Erlangen, Germany.

Andrei Gafita

Ahmanson Translational Theranostics, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, CA, USA.

Michael J Morris

Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Stefano Fanti

IRCCS AOU di Bologna, Bologna, Italy.

Wolfgang A Weber

Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.

Thomas A Hope

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.

Michael S Hofman

Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

Wolfgang Peter Fendler

Department of Nuclear Medicine, University Hospital Essen, Essen, Germany; PET Committee of the German Society of Nuclear Medicine, Göttingen, Germany.

Matthias Eiber

Bavarian Cancer Research Center (BZKF), Erlangen, Germany; Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.